Massachusetts solidifies position as a haven for biotech jobs

Thursday, October 7, 2010 03:19 PM

Massachusetts has improved its position as a nation-leading biotechnology cluster, increasing jobs not just in research & development, but also in manufacturing. The latest data from MassBio shows Massachusetts was one of just four states that added biotechnology manufacturing jobs in the last decade. Overall, Massachusetts has improved its position within the physical sciences, as defined by industry concentration, by 100 percent.

"Despite the difficult economy, we continue to be the top choice for biotech and pharmaceutical companies looking to discover the latest cures and therapies, and the top choice for the people who invest in those companies," said Robert K. Coughlin, MassBio president and CEO. Venture capital figures have also held steady, with the first two quarters of investment in 2010 reaching an historic high. The statistics, in the MassBio Industry Snapshot, are compiled annually.

Also, Massachusetts’ biopharma industry employment reached an all-time high in 2009, continuing the industry's six-year growth, and now accounts for $4.2 billion in payroll. Between 2005 and 2009, Massachusetts biotech jobs grew 19.7 percent, compared with 5 percent growth for all jobs in the state. Companies headquartered in Massachusetts have commercialized 141 products that treat 90 different medical conditions, for a U.S. patient population totaling over 160 million people.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs